Alle Fälle anzeigen
UPC APP 907/2025
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieSonstige prozessuale
- Parteien
- Kläger
- Sanofi Mature IP
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Vertreter: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)Beklagte- Accord Healthcare S.L.U.
- Accord Healthcare GmbH (AT)
- Accord Healthcare B.V.
- Accord Healthcare GmbH (DE)
- Accord Healthcare Italia Srl
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare AB
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Reddy Pharma SAS
- betapharm Arzneimittel GmbH
- Dr Reddy's Srl
- Zentiva France
- Zentiva Pharma GmbH
- Zentiva, k.s.
Vertreter: Jules Fabre (Pinsent Mason); Arjan Reijns (Pinsent Mason); Louise Millot (Pinsent Mason); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Andreas Ledl (Maiwald); Anja Lunze (Taylor Wessing); Elisabeth Greiner (df-mp) - Division
- Munich LD
- Richter
- Matthias Zigann · Presiding Judge / Judge-Rapporteur (Munich Local Division)
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 17. Jan. 2025
Entscheidungen
- 2025-01-17Application Rop305
The Munich Local Division issued a procedural order in multiple related infringement actions by Sanofi against various generic manufacturers (Accord, STADA, Dr. Reddy's, Zentiva) concerning EP 2 493 466. The order addressed the substitution of Sanofi Mature IP by Sanofi SA as new patent proprietor following Sanofi Mature IP's dissolution, and the consequential procedural steps under R. 310 RoP.
Rechtsfragen:Change of party: substitution of patent proprietor following dissolution (R. 310 RoP)R. 305 RoP applicationMulti-case pharmaceutical patent infringement proceedings
Dokumente
- 65DD6F8DBE3E1F014557C5F4AFC6E4B9_en.pdf2025-01-17EN